Journal of Psychiatric Research
June 2, 2026
Daniel J. Kruger, Audrey Czerew, Leigh Farquhar et al.
Most academic psychedelic research is clinically oriented, with industry research primarily focusing on the medicalization of these substances. Given the rapid policy changes and the surge in interest among researchers and the public, it is imperative to assess and document the research priorities of the broader psychedelic community. This study aimed to identify these priorities through an...
Scientific Reports
April 15, 2026
Jacob S. Aday, Nicolas G. Glynos, Anne Baker et al.
Psychedelic drugs show promise in facilitating a variety of long-term psychological changes, but they may also lead to unexpected major life changes that have not been captured by measures typically used in clinical trials. The Psychedelic-related Major Life Changes Questionnaire ( P-MLCQ ) was created to assess psychedelic-related major life changes across 10 different domains and evaluated in...
Journal of Neuroscience
December 19, 2025
Nicolas G. Glynos, Emma R. Huels, Trent Groenhout et al.
11 citations
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that is being investigated for the treatment of psychiatric disorders. Although the neurophysiological effects of DMT in humans are well characterized, similar studies in animal models and data on the neurochemical effects of DMT are generally lacking, which are critical for a mechanistic understanding. Here, we combined behavioral...
Journal of psychopharmacology (Oxford, England)
May 1, 2025
Niloufar Pouyan, Jacob S. Aday, Steven E. Harte et al.
1 citation
Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals' perception of self with a particular medical condition, broadly termed self-condition enmeshment. This study aimed to evaluate changes in PRISM...
Universität Zürich, ZORA
May 1, 2025
Niloufar Pouyan, Jacob S. Aday, Steven E. Harte et al.
Background: Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals' perception of self with a particular medical condition, broadly termed self-condition enmeshment. Aims: This study aimed to evaluate...
Journal of Psychoactive Drugs
April 22, 2025
Nicolas G. Glynos, Mallet R Reid, Jacob S. Aday et al.
4 citations
People of Color have been under-included in psychedelic-assisted therapy (PAT) research. Researchers have argued that systemic issues resulting in harms to communities of color like the War on Drugs and recurrent exposure to discrimination in healthcare settings may reduce their willingness to engage in PAT research. However, there are no empirical data regarding People of Color's trust or...
Frontiers in Pain Research
March 18, 2025
Jenna McAfee, Avinash Hosanagar, Vijay Tarnal et al.
18 citations
Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM. Methods...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2025
Daniel J. Kruger, Jacob S. Aday, Christopher W Fields et al.
19 citations
Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse...
British Journal of Pain
February 11, 2025
Anne Baker, Stephanie Lake, Philippe Lucas et al.
7 citations
Psychedelic substances have shown preliminary efficacy for several neuropsychiatric disorders and are currently being investigated for chronic pain conditions. However, few studies have investigated outcomes of naturalistic psychedelic use among individuals with chronic pain, and none have assessed psychedelic-related changes in substance use patterns in this population. In a cross-sectional...
Journal of Psychoactive Drugs
2025
Jamarie Geller, Nicolas G. Glynos, Andrew Lemmen et al.
This study aimed to characterize attitudes and identify gaps in trainee knowledge and education that may impact the field's readiness for the reemergence of psychedelic use in psychiatry. A two-part survey was sent out targeting medical and allied professional trainees who may interact with patients using or planning to use psychedelics therapeutically. Collected data for part one characterized...
Journal of Psychoactive Drugs
September 19, 2024
Anne Baker, Niloufar Pouyan, Julie Barron et al.
9 citations
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners. We conducted an anonymous online survey of individuals who...
Frontiers in Psychiatry
2024
Nicolas G. Glynos, Jacob S. Aday, Daniel J. Kruger et al.
15 citations
Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and neglecting to include non-North American and European populations. We conducted a global, cross-sectional online survey of adults (n = 5,268, 47.2% women) self-reporting past or current psychedelic use and...
Frontiers in Psychiatry
August 4, 2023
Kasey Cox, Cody Weston, Moss Herberholz et al.
Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and...
Journal of Psychoactive Drugs
July 29, 2023
Nicolas G. Glynos, Daniel J. Kruger, Nicholas Kolbman et al.
ABSTRACT Naturalistic psychedelic use among Canadians is common. However, interactions about psychedelic use between patients and clinicians in Canada remain unclear. Via an anonymous survey, we assessed health outcomes and integration of psychedelic use with health care providers (HCP) among Canadian adults reporting past use of a psychedelic. The survey included 2,384 participants, and most...
Scientific Reports
January 6, 2023
Nicolas G. Glynos, Lily Carter, Soo Jung Lee et al.
17 citations
Indolethylamine N-methyltransferase (INMT) is a transmethylation enzyme that utilizes the methyl donor S-adenosyl-L-methionine to transfer methyl groups to amino groups of small molecule acceptor compounds. INMT is best known for its role in the biosynthesis of N,N-Dimethyltryptamine (DMT), a psychedelic compound found in mammalian brain and other tissues. In mammals, biosynthesis of DMT is...
Journal of Psychoactive Drugs
2023
Daniel J. Kruger, Nicolas G. Glynos, Christopher W Fields et al.
10 citations
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use of and harm reduction practices for psychedelics in the naturalistic use landscape. The current study piloted an assessment instrument with questions on legal status, therapeutic potential, and side effects of psychedelics among people reporting...
Deep Blue (University of Michigan)
2023
Nicolas G. Glynos
N,N-dimethyltryptamine (DMT) belongs to a class of drugs known as serotonergic psychedelics, which produce profound shifts in consciousness by dramatically altering perception and causing hallucinatory phenomena. In humans, DMT has a rapid onset and the effects, which include feelings of dissociation from external reality, entering into an ‘otherworldly dimension’, and intense internal visual...
Journal of Psychoactive Drugs
January 10, 2022
Nicolas G. Glynos, Jennifer Pierce, Alan K. Davis et al.
39 citations
Fibromyalgia (FM) is a difficult to treat chronic pain condition for which there is strong interest in alternative treatments. There is growing interest in the potential of psychedelic substances (e.g., psilocybin) in conjunction with psychotherapy to treat chronic pain. Via a cross-sectional, anonymous, online survey, we aimed to characterize knowledge, perceptions, and past use of...